

## **List of Figures**

Figure 1.1 Absorption mechanisms implemented by lipidic nanocarriers for improving the oral bioavailability of drug substances .....	7
Figure 1.2 Possible transcellular mechanism of nanocarrier uptake by the intestinal barrier .....	8
Figure 2.1 HIV replication steps.....	19
Figure 2.2 The HIV-1 protease complex with an inhibitor.....	23
Figure 2.3 Schematic transverse sections of peyer's patch lymphoid follicle and overlying follicle associated epithelium (FAE) .....	28
Figure 2.4 Schematic representation of a solid lipid nanoparticle.....	33
Figure 2.5 Structure of Hydrogenated castor oil.....	39
Figure 2.6 Schematic representation of a nanoemulsion droplet.....	42
Figure 2.7 Schematic representation of the critical steps in oral drug absorption and the possible influences of lipid based formulations.....	52
Figure 2. 8 Structural formula of Darunavir .....	55
Figure 2. 9 Structural formula of Atazanavir sulfate .....	58
Figure 3.1 UV spectrum of Darunavir (10 ppm) .....	84
Figure 3.2 Overlay Spectra of Darunavir.....	85
Figure 3.3 Calibration plot of Darunavir in Methanol: DCM (7:3) at 267 nm.....	85
Figure 3.4 UV interference result of (a) Darunavir solution and mixture of Darunavir and glyceryl behenate and (b) Darunavir solution and mixture of Darunavir and glyceryl palmitostearate .....	87
Figure 3.5 UV interference result of (a) Darunavir solution and mixture of Darunavir and hydrogenated castor oil and (b) Darunavir solution and mixture of Darunavir and trimyristin.....	88
Figure 3.6 UV interference result of (a) Darunavir solution and mixture of Darunavir and tripalmitin and (b) Darunavir solution and mixture of Darunavir and sodium oleate .....	88
Figure 3.7 Overlay Spectra of Darunavir.....	89
Figure 3.8 Calibration plot of Darunavir in SGF: methanol (1:0.5) at 267 nm .....	89
Figure 3.9 Overlay Spectra of Darunavir.....	92
Figure 3.10 Calibration plot of Darunavir in SIF: methanol (1:0.5) at 267 nm.....	93
Figure 3.11 Chromatogram of Darunavir using HPLC .....	95
Figure 3.12 Calibration plot of Darunavir using HPLC .....	95
Figure 3.13 Mass spectrum of Darunavir .....	97
Figure 3.14 Standard peaks obtained from LCMS analysis (blank sample, 25, 50 and 100 ng/ml Darunavir samples).....	98
Figure 3.15 Standard peaks obtained from LCMS analysis (250, 500, 750 and 1000 ng/ml Darunavir samples).....	99
Figure 3.16 Calibration plot of Darunavir using LCMS in plasma .....	99

Figure 3.17 Standard peaks obtained from LCMS analysis of Darunavir in spleen.....	101
Figure 3.18 Calibration plot of Darunavir using LCMS in spleen .....	101
Figure 3.19 UV spectrum of ATZ (10 µg/ml) .....	102
Figure 3.20 Overlay Spectra of ATZ .....	103
Figure 3.21 Calibration plot of ATZ in Methanol: DCM (7:3) at 267 nm .....	103
Figure 3.22 UV interference result of (a) ATZ solution and mixture of ATZ and glyceryl behenate and (b) ATZ solution and mixture of ATZ and glyceryl palmitostearate .....	105
Figure 3.23 UV interference result of (a) ATZ solution and mixture of ATZ and hydrogenated castor oil and (b) ATZ solution and mixture of ATZ and trimyristin.....	106
Figure 3.24 UV interference result of (a) ATZ solution and mixture of ATZ and tripalmitin and (b) ATZ solution and mixture of ATZ and sodium oleate .	106
Figure 3.25 Overlay spectra of ATZ in Simulated gastric fluid .....	107
Figure 3.26 Calibration plot of ATZ in SGF: methanol (1:0.5) at 249 nm.....	107
Figure 3.27 Overlay spectra of ATZ in simulated intestinal fluid: methanol (1:0.5) .....	110
Figure 3.28 Calibration plot of ATZ in SIF: methanol (1:0.5) at 249 nm .....	111
Figure 3.29 HPLC Chromatogram of Atazanavir sulfate .....	113
Figure 3.30 Calibration plot of Atazanavir sulfate using HPLC .....	113
Figure 3.31 Chromatogram of Atazanavir sulfate in plasma.....	115
Figure 3.32 Calibration plot of Atazanavir sulfate in plasma.....	116
Figure 3.33 Chromatogram of Atazanavir sulfate in spleen .....	118
Figure 3.34 Calibration plot of Atazanavir sulfate in spleen .....	118
 Figure 4.1 Mass spectrum of peptide .....	 122
Figure 4.2 Diagrammatic representation of preparation of solid lipid nanoparticles .....	124
Figure 4.3 Thermal cycle for freeze drying .....	127
Figure 4.4 Schematic representation of peptide coupling to nanoparticles .....	130
Figure 4.5 Thermal graph of freeze drying cycle for lyophilization of Darunavir loaded SLNs.....	144
Figure 4.6 Thermal graph of freeze drying cycle for lyophilization of ATZ loaded SLNs .....	153
 Figure 5.1 Particle size distribution of Dar-SLN1 formulation .....	 171
Figure 5.2 Particle size distribution of Dar-SLN2 formulation .....	171
Figure 5.3 Particle size distribution of Dar-SLN3 formulation .....	171
Figure 5.4 Zeta potential of Dar-SLN1 formulation by Malvern Zetasizer.....	172
Figure 5.5 Zeta potential of Dar-SLN2 formulation by Malvern Zetasizer.....	172
Figure 5.6 Zeta potential of Dar-SLN3 formulation by Malvern Zetasizer.....	172
Figure 5.7 Transmission electron microscopic image of Dar-SLN1 formulation .....	173
Figure 5.8 Transmission electron microscopic image of Dar-SLN2 formulation .....	174
Figure 5.9 Transmission electron microscopic image of Dar-SLN3 formulation .....	174

Figure 5.10 Field emission scanning electron microscopic image of Dar-SLN1 formulation.....	175
Figure 5.11 Field emission scanning electron microscopic image of Dar-SLN2 formulation.....	175
Figure 5.12 Field emission scanning electron microscopic image of Dar-SLN3 formulation.....	176
Figure 5.13 Overlay plot of DSC thermograms of pure drug, lipid and physical mixtures of drug and lipid in various ratios .....	177
Figure 5.14 Overlay plot of DSC thermograms of (a) pure drug, (b) placebo solid lipid nanoparticles and (c) Darunavir loaded solid lipid nanoparticles (Dar-SLN2).....	177
Figure 5.15 FT-IR spectrum of Darunavir .....	178
Figure 5.16 FT-IR spectrum of hydrogenated castor oil.....	179
Figure 5.17 FT-IR spectrum of physical mixture of drug and HCO .....	179
Figure 5.18 FT-IR spectrum of placebo solid lipid nanoparticles .....	180
Figure 5.19 FT-IR spectrum of Darunavir loaded SLNs (Dar-SLN02).....	180
Figure 5.20 <i>In-vitro</i> drug release profiles of plain Darunavir suspension and Darunavir loaded nanoparticles .....	183
Figure 5.21 SDS Page images. Lane 1,2,3 = Peptide (standard), Lane 3,4,5 = Formulation (quantity equivalent to standard peptide).....	184
Figure 5.22 Calibration plot of BSA.....	185
Figure 5.23 Transmission electron microscopic image of DNE-3 formulation.....	187
Figure 5.24 <i>In-vitro</i> drug release profiles of Darunavir loaded nanoemulsion (DNE3) in comparison with plain Darunavir suspension .....	188
Figure 5.25 Plot of cumulative % drug release from DNE-3 versus root of time .....	189
Figure 5.26 Particle size distribution of ALN-23 formulation by Malvern Zetasizer .....	190
Figure 5.27 Zeta potential distribution of ALN-23 formulation by Malvern Zetasizer.....	191
Figure 5.28 Transmission electron microscopic image of ALN-23 formulation.....	192
Figure 5.29 Field emission scanning electron microscopic image of ALN-23 formulation.....	192
Figure 5.30 Overlay plot of DSC thermograms of (a) pure ATZ, (b) lipid, (c) physical mixture of drug and lipid and (d) lyophilized ATZ loaded SLNs .....	193
Figure 5.31 FT-IR spectrum of Atazanavir sulfate .....	194
Figure 5.32 FT-IR spectrum of physical mixture of ATZ and HCO .....	194
Figure 5.33 FT-IR spectrum of lyophilized formulation ALN-23.....	195
Figure 5.34 SDS Page images. Lane 1,2,3 = Peptide (standard), Lane 3,4,5 = Formulation (quantity equivalent to standard peptide).....	196
Figure 5.35 <i>In-vitro</i> drug release profiles of plain ATZ suspension and ATZ loaded nanoparticles .....	198
Figure 6.1 MTT dye reduction by mitochondrial reductase enzyme of viable cells .....	202
Figure 6.2 Diagram of Caco-2 monolayer grown on a permeable filter support.....	205

Figure 6.3 Haemocytometer diagram indicating the 16 corners which should be used for counting .....	208
Figure 6.4 Schematic representation of preparation of various samples for MTT assay .....	210
Figure 6.5 Viability of Caco-2 cells in presence of various samples of placebo SLNs and Darunavir loaded SLNs.....	217
Figure 6.6 % relative reduction in cell uptake of Darunavir in presence of various endocytic inhibitors (n=6).....	218
Figure 6.7 % relative reduction in cell uptake of Atazanavir sulfate in presence of various endocytic inhibitors (n=6) .....	218
Figure 6.8 Cell uptake in Molt-4 cell line. (A) DAPI-nuclei staining (B) SLNs (C) Merged .....	222
Figure 6.9 Cell uptake in Caco-2 cell line. (A) DAPI-nuclei staining (B) SLNs (C) Merged .....	223
Figure 7.1 Comparison of plasma concentration vs time profile after oral administration of Darunavir suspension, marketed tablet, Dar-SLN1, Dar-SLN2 and Dar-SLN3 formulations to rats.....	235
Figure 7.2 Plasma concentration of Darunavir from Darunavir suspension and Dar-SLN2 after intragastric administration.....	238
Figure 7.3 Comparison of AUC <sub>0-t</sub> obtained after intragastric administration of Darunavir suspension and optimized Darunavir loaded SLNs (Dar-SLN2).....	239
Figure 7.4 Plasma concentration of Darunavir from Darunavir suspension and Dar-SLN2 after intraduodenal administration .....	240
Figure 7.5 Comparison of AUC <sub>0-t</sub> obtained after intraduodenal administration of Darunavir suspension and optimized Darunavir loaded SLNs (Dar-SLN2).....	240
Figure 7.6 Plasma concentration versus time profile of Darunavir from Dar-SLN2 in presence and absence of cycloheximide .....	242
Figure 7.7 Comparison of AUC <sub>0-t</sub> of Darunavir upon Dar-SLN2 administration in presence and absence of cycloheximide .....	242
Figure 7.8 Comparison of Darunavir concentration obtained in liver, spleen, kidney, and heart upon administration of plain drug suspension and Darunavir loaded SLNs.....	244
Figure 7.9 Comparison of Darunavir concentration obtained in lung, stomach, intestine and brain upon administration of plain drug suspension and Darunavir loaded SLNs .....	245
Figure 7.10 Photographic image of section of intestine before treatment with acetic acid.....	247
Figure 7.11 Photographic image of section of intestine after treatment with acetic acid.....	247

Figure 7.12 Comparison of Darunavir amount in PP and Non-PP region upon oral administration of Dar-SLNs.....	248
Figure 7.13 Comparison of plasma concentration vs time profile after oral administration of peptide grafted Darunavir SLNs (Pept-Dar-SLN) and non-peptide grafted Darunavir SLNs (Dar-SLN2) rats (n=3).....	250
Figure 7.14 Comparison of Darunavir concentration obtained in liver, spleen, kidney, and heart upon administration of peptide grafted- and non-peptide grafted SLNs of Darunavir .....	252
Figure 7.15 Comparison of Darunavir concentrations obtained in lung, stomach, intestine and brain upon administration of peptide grafted- and non-peptide grafted SLNs of Darunavir.....	253
Figure 7.16 Comparison of plasma concentration versus time profile after oral administration of Darunavir nanoemulsion, Darunavir suspension and marketed tablet .....	255
Figure 7.17 Comparison of Darunavir concentration obtained in liver, spleen, kidney, and heart upon administration of plain drug suspension and Darunavir loaded nanoemulsion .....	259
Figure 7.18 Comparison of Darunavir concentration obtained in lung, stomach, intestine and brain upon administration of plain drug suspension and Darunavir loaded lipid nanoemulsion.....	260
Figure 7.19 Comparison of plasma concentration versus time profile after oral administration of plain ATZ suspension, ATZ loaded SLNs and peptide grafted ATZ loaded SLNs.....	262
Figure 7.20 Comparison of ATZ concentration obtained in liver, spleen, kidney, and heart upon administration of ATZ suspension, ATZ loaded SLNs and peptide grafted ATZ loaded SLNs.....	265
Figure 7.21 Comparison of ATZ concentration obtained in lung, stomach, intestine and brain upon administration of ATZ suspension, ATZ loaded SLNs and peptide grafted ATZ loaded SLNs .....	266